URGN
Urogen Pharma Ltd
NASDAQ · Biotechnology
$21.35
+0.83 (+4.04%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 98.69M | 79.93M | 558.77M | 574.93M | 620.56M |
| Net Income | -138,507,519 | -100,969,356 | 35.72M | 29.33M | 36.90M |
| EPS | — | — | — | — | — |
| Profit Margin | -140.4% | -133.3% | 6.4% | 5.1% | 6.0% |
| Rev Growth | +23.5% | +23.5% | -6.2% | -7.8% | +0.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 379.39M | 316.20M | 293.87M |
| Total Equity | — | — | 421.47M | 463.52M | 437.50M |
| D/E Ratio | — | — | 0.90 | 0.68 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -131,107,032 | -100,884,238 | 53.38M | 65.79M | 68.95M |
| Free Cash Flow | — | — | 30.74M | 30.48M | 44.33M |